In subclinical AF, the benefit of apixaban vs. aspirin on stroke or systemic embolism trended higher with CHA2DS2-VASc >4

Giulio Francesco Romiti; Giovanni Talerico

doi:10.7326/ANNALS-24-02625-JC

In subclinical AF, the benefit of apixaban vs. aspirin on stroke or systemic embolism trended higher with CHA₂DS₂-VASc >4

Ann Intern Med. 2024 Nov;177(11):JC125. doi: 10.7326/ANNALS-24-02625-JC. Epub 2024 Nov 5.

Authors

Giulio Francesco Romiti¹, Giovanni Talerico²

Affiliations

¹ Sapienza-University of Rome, Rome, Italy (G.F.R.).
² Azienda Ospedaliera San Giovanni Addolorata, Rome, Italy (G.T.).

PMID: 39496171
DOI: 10.7326/ANNALS-24-02625-JC

Abstract

Lopes RD, Granger CB, Wojdyla DM, et al. Apixaban vs aspirin according to CHA₂DS₂-VASc score in subclinical atrial fibrillation: insights from ARTESiA. J Am Coll Cardiol. 2024;84:354-364. 39019530.

MeSH terms

Aged
Aspirin* / adverse effects
Aspirin* / therapeutic use
Atrial Fibrillation* / complications
Atrial Fibrillation* / drug therapy
Embolism / etiology
Embolism / prevention & control
Factor Xa Inhibitors* / adverse effects
Factor Xa Inhibitors* / therapeutic use
Female
Humans
Male
Platelet Aggregation Inhibitors / adverse effects
Platelet Aggregation Inhibitors / therapeutic use
Pyrazoles* / adverse effects
Pyrazoles* / therapeutic use
Pyridones* / adverse effects
Pyridones* / therapeutic use
Risk Assessment
Stroke* / prevention & control

Substances

Pyridones
apixaban
Aspirin
Pyrazoles
Factor Xa Inhibitors
Platelet Aggregation Inhibitors